There will be a HazMat fee per item when shipping a dangerous goods. The HazMat fee will be charged to your UPS/DHL/FedEx collect account or added to the invoice unless the package is shipped via Ground service. Ship by air in Excepted Quantity (each bottle), which is up to 1g/1mL for class 6.1 packing group I or II, and up to 25g/25ml for all other HazMat items.
Type
HazMat fee for 500 gram (Estimated)
Excepted Quantity
USD 0.00
Limited Quantity
USD 15-60
Inaccessible (Haz class 6.1), Domestic
USD 80+
Inaccessible (Haz class 6.1), International
USD 150+
Accessible (Haz class 3, 4, 5 or 8), Domestic
USD 100+
Accessible (Haz class 3, 4, 5 or 8), International
D-I03, with a KD of 25.8 µM, is a selective inhibitor of RAD52. It specifically targets RAD52-dependent single-strand annealing (SSA) and D-loop formation, with IC50s of 5 µM and 8 µM, respectively. D-I03 inhibits the growth of BRCA1- and BRCA2-deficient cells, and prevents the formation of damage-induced RAD52 foci, while not affecting RAD51 foci induced by Cisplatin[1][2].
体内研究
Treatment with D-I03 (50 mg/kg/day; intraperitoneal injection; daily; for 7 days) decreases the growth of BRCA1-deficient MDA-MB-436 tumors in nu/nu mice. The combination of talazoparib and D-I03 does not impact the growth of BRCA1-proficient tumors and does not cause significant toxicity to normal tissues and organs[3].
Pharmacokinetic and toxicity studies show that the maximum tolerated dose of D-I03 is ≥50 mg/kg, with a half-life (t1/2) of 23.4 hours, leading to a maximal concentration of >1 μM in peripheral blood[1].
体外研究
Treatment with D-I03 (0-10 μM; on days 1 and 3; Capan-1 and UWB1.289 cells) selectively inhibited the growth of Capan-1 and UWB1.289 cells in a concentration-dependent manner[1].
D-I03 inhibits RAD52 foci formation induced by cisplatin in BCR-ABL1-positive BRCA1-deficient 32Dcl3 murine hematopoietic cells expressing GFP-RAD52. In the presence of D-I03 (2.5 μM), the percentage of cells with RAD52 foci decreases from 38.7% to 17.1%, while the percentage of cisplatin-treated cells without foci increases from 48.4% to 71.9%. D-I03 has no effect on RAD51 foci induced by cisplatin. Moreover, D-I03 alone neither induces RAD51 foci nor RAD52 foci (in BRCA1-deficient cells), indicating its low genotoxicity[1].
搜索
HazMat Fee +
